Show simple item record

dc.contributor.authorGriensven, JVen
dc.contributor.authorDiro, Ermiasen
dc.date.accessioned2018-07-30T12:54:45Z
dc.date.available2018-07-30T12:54:45Z
dc.date.issued2018-07
dc.identifier.urihttp://hdl.handle.net/10144/619234
dc.descriptionResearch Protocolen
dc.description.abstractAim To study the asymptomatic period preceding the onset of active VL in HIV‐infected individuals from VL endemic regions in Ethiopia as an avenue to develop an evidence‐based screen and treat strategy to prevent progression to active VL.Primary: 1. To estimate the prevalence of asymptomatic Leishmania infection . 2. To estimate the incidence rate of asymptomatic Leishmania infection. 3. To describe the evolution of Leishmania infection markers over time. 4. To estimate the incidence rate of active VL. 5. To identify risk factors associated with the development of active VL. 6. To translate these risk factors into a clinical prognostic tool to identify individuals at high risk to develop active VL within 12 months . Secondary: 1. To identify patterns in host immune markers that are associated with asymptomatic Leishmania infection. 2. To describe the evolution of host immune markers over time. 3. To identify patterns in host immune markers that are associated with treatment failure. 4. To identify patterns in host immune markers that are associated with VL relapse.
dc.language.isoenen
dc.rightsThese materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen
dc.subjectvisceral leishmaniasiaen
dc.subjectHIVen
dc.subjectPreLeisHen
dc.titlePredicting Visceral Leishmaniasis in HIV Infected Patients (PreLeisH)en
dc.typeOtheren
dc.contributor.departmentMSF-OCAen
refterms.dateFOA2019-02-21T13:39:30Z
html.description.abstractAim To study the asymptomatic period preceding the onset of active VL in HIV‐infected individuals from VL endemic regions in Ethiopia as an avenue to develop an evidence‐based screen and treat strategy to prevent progression to active VL.Primary: 1. To estimate the prevalence of asymptomatic Leishmania infection . 2. To estimate the incidence rate of asymptomatic Leishmania infection. 3. To describe the evolution of Leishmania infection markers over time. 4. To estimate the incidence rate of active VL. 5. To identify risk factors associated with the development of active VL. 6. To translate these risk factors into a clinical prognostic tool to identify individuals at high risk to develop active VL within 12 months . Secondary: 1. To identify patterns in host immune markers that are associated with asymptomatic Leishmania infection. 2. To describe the evolution of host immune markers over time. 3. To identify patterns in host immune markers that are associated with treatment failure. 4. To identify patterns in host immune markers that are associated with VL relapse.


Files in this item

Thumbnail
Name:
2_160603_PreLeisH_Procotol_v2.0.doc
Size:
798Kb
Format:
Microsoft Word
Description:
Research Protocol

This item appears in the following Collection(s)

Show simple item record